Form 4: CEO James Rolke Disposes of REVB Shares for Tax Obligations

Revelation Biosciences CEO James Rolke sold 10,115 shares to cover mandatory tax withholding obligations related to restricted stock vesting.

Summary

• James Rolke, CEO of Revelation Biosciences, Inc. (REVB), disposed of 10,115 shares of common stock on April 30, 2026.
• The shares were sold at a weighted average price of $1.13 per share, with individual transaction prices ranging from $1.12 to $1.14.
• Following this transaction, the reporting person maintains beneficial ownership of 214,738 shares of common stock.
• The sale was a mandatory transaction executed by the issuer to satisfy tax withholding requirements upon the vesting of restricted stock awards.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory administrative action to satisfy tax obligations rather than a discretionary market trade.

Positives

• The transaction was non-discretionary, indicating it was not a voluntary divestment based on market sentiment or company outlook.

Negatives

• The reduction in direct share ownership by the CEO, though mandatory for tax purposes, decreases the total equity stake held by the executive.

Risks

• The company remains subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approval processes.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing, as it is a standard disclosure of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that mandatory tax withholding sales are common in the biotechnology sector, where equity-based compensation is a primary tool for executive retention. Such filings are generally viewed as neutral by the market as they do not reflect a change in management's confidence in the company's long-term prospects.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling tax liabilities associated with restricted stock unit (RSU) vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.

Key Dates

Keywords

REVB, Revelation Biosciences, Insider Trading, Form 4, Biotech, Executive Compensation